These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Ugandan children receive lower-strength Aluvia. AIDS Patient Care STDS; 2008 Jan; 22(1):86-7. PubMed ID: 18453040 [No Abstract] [Full Text] [Related]
29. Atazanavir: new indication. First-line treatment: fewer gastrointestinal disorders but more cases of jaundice and a risk of torsades de pointes. Prescrire Int; 2009 Jun; 18(101):104. PubMed ID: 19637415 [TBL] [Abstract][Full Text] [Related]
30. [Pharmacologic interest in HIV protease inhibitors: concepts and utilization]. Peytavin G Med Mal Infect; 2006 Jul; 36 Suppl 2():S191-7. PubMed ID: 17075996 [No Abstract] [Full Text] [Related]
38. Clinical experience with the combined use of lopinavir/ritonavir and rifampicin. L'homme RF; Nijland HM; Gras L; Aarnoutse RE; van Crevel R; Boeree M; Brinkman K; Prins JM; Juttmann JR; Burger DM AIDS; 2009 Apr; 23(7):863-5. PubMed ID: 19352137 [TBL] [Abstract][Full Text] [Related]
39. Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial. Soulié C; Assoumou L; Ghosn J; Duvivier C; Peytavin G; Ait-Arkoub Z; Molina JM; Costagliola D; Katlama C; Calvez V; Marcelin AG AIDS; 2009 Jul; 23(12):1605-8. PubMed ID: 19487903 [TBL] [Abstract][Full Text] [Related]
40. CMV DNA levels and CMV gB subtypes in ART-naive HAART-treated patients: a 2-year follow-up study in The Netherlands. Goossens VJ; Wolffs PF; van Loo IH; Bruggeman CA; Verbon A AIDS; 2009 Jul; 23(11):1425-9. PubMed ID: 19531930 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]